#Market News January 9, 2018 / 3:42 PM / Updated 25 minutes ago BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa Reuters Staff 1 Min Read 
Jan 9 (Reuters) - Inflarx Nv: 
* INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA 
* INFLARX NV - ‍INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1 OF 2018​ Source text for Eikon: Further company coverage: